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http://dx.doi.org/10.1016/j.jacl.2015.11BACKGROUND: Moderate hypertriglyceridemia is frequently associated with central obesity, insu-
lin resistance, and atherogenic dyslipidemia. We showed previously that moderately obese men with
hypertriglyceridemia have reduced fatty acid oxidation postabsorptively and postprandially. In the pre-
sent study, we examined the oxidation of fatty acids in normotriglyceridemic men.
OBJECTIVE: The study objective was to determine the relation between plasma triglyceride levels
and fatty acid oxidation in normotriglyceridemic men.
STUDY DESIGN: Twenty-four healthy, nonobese White and African American men participated in a
cross-sectional metabolic study for evaluation of fatty acid oxidation. Men were healthy, and none took
hypolipidemic or hypoglycemic agents. They ingested 200 mg of fat/hour/kg of body weight over a 10-
hour period. Plasma levels of triglyceride, nonesterified fatty acids, 3-b-hydroxybutyrate, insulin, and
glucagon were measured postabsorptively and postprandially. Chylomicron-triglyceride halflife was
also calculated.
RESULTS: Nonobese White and African-American men had similar anthropometry, levels of plasma
triglyceride, lipoprotein cholesterol, nonesterified fatty acids, 3-b-hydroxybutyrate, insulin, and
glucagon postabsorptively and postprandially. For the group as a whole, there was a positive and signif-
icant correlation between plasma fatty acids and 3-b-hydroxybutyrate and an inverse association between
plasma triglyceride levels and 3-b-hydroxybutyrate at baseline. All subjects had increased levels of me-
tabolites of interest postprandially. However, there were no significant changes in plasma insulin,
glucagon, or the ratio of insulin to glucagon. The postprandial levels of 3-b-hydroxybutyrate correlated
positively with nonesterified fatty acids and inversely with the half-life of chylomicron triglyceride.
CONCLUSION: Normotriglyceridemia is strongly associated with oxidation of fatty acids by the liver
suggesting the possibility that the fatty acid oxidation pathway is a potential target of intervention to pre-
vent hypertriglyceridemia and concomitant fatty liver.
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.018Introduction
Hypertriglyceridemia is a component of atherogenic
dyslipidemia and the metabolic syndrome.1 The latter im-
parts increased risk for atherosclerotic cardiovascularis is an open access article under the CC BY-NC-ND license (http://
Figure 1 Plot of plasma triglyceride levels during an extended
fat tolerance test for the group as a whole. This curve shows the
rise in plasma triglyceride levels and the eventual attainment of
a steady state.
284 Journal of Clinical Lipidology, Vol 10, No 2, April 2016disease. Fasting triglycerides are carried by apolipoprotein
B-containing triglyceride-rich lipoproteins. These lipopro-
teins almost certainly contribute significantly to atheroscle-
rotic cardiovascular disease risk accompanying atherogenic
dyslipidemia. The mechanisms underlying hypertriglyceri-
demia continue to be the subject of great interest. The asso-
ciation of hypertriglyceridemia with the metabolic
syndrome suggests important roles for obesity (particularly
abdominal obesity), elevated nonesterified fatty acids
(NEFA), and accumulation of ectopic fat in the liver. This
is exemplified by the so-called ‘‘hypertriglyceridemia-
waist’’ syndrome.2
One defense against ectopic fat accumulation and
hypertriglyceridemia may be increased oxidation of fatty
acids in the liver. We have previously shown that moder-
ately obese patients with hypertriglyceridemia have a
reduced level of 3-b-hydroxybutyrate.3 The latter is a mea-
sure of fatty acid oxidation.4,5 This association suggests
that failure to enhance fatty acid oxidation with an
increased fat load on the liver leads to a shunting of excess
TGs into triglyceride-rich lipoproteins. In the present study,
we examined whether fatty acid oxidation correlates with
fasting triglycerides (TG) levels over the normal range.
We also examined whether fatty acid oxidation increases
in response to oral fat loading; if so, this could also protect
against ectopic fat accumulation in the liver.
Study design and methods of procedure
This study was designed to examine fatty acid oxidation
in healthy, nonobese (waist girth , 90 cm) men with
normal plasma TG (,150 mg/dL). Subjects were self-
identified as White (Europid) or African American. The
study volunteers were seen at the Clinical Translational
Research Center (CTRC) of the University of Texas
Southwestern Medical Center at Dallas where the study
was conducted. The study was approved by the Institutional
Review Boards for Investigation in Humans of the Univer-
sity of Texas Southwestern Medical Center and the VA
North Texas Health Care System. All enrollees were from
the Dallas-Fort Worth area and were seen at the CTRC.
Men were evaluated for inclusion into the study, and the
screening procedures involved a brief clinical history and
physical examination, anthropometry, measurement of
blood pressure and vital signs and a comprehensive
metabolic panel measured after a 12 hour fast. Subjects
were excluded from the study if they had history of
hypertriglyceridemia, liver disease, or persistent elevation
of transaminases (.1.5 ! ULN) or renal disease, infec-
tious disease, diabetes mellitus, uncontrolled hypertension,
hypothyroidism, or endocrine disorders that precluded
participation into the study. Subjects with history of heart
disease also were excluded from the study. None of the
study volunteers were taking hypolipidemic agents or
supplements affecting levels of plasma triglycerides at the
time of the study. None reported history of excess alcohol
intake.Forty-three healthy males were recruited into the study.
They were identified through advertisements from the
Dallas-Fort Worth community. Sixteen men did not qualify
to participate in the study, and 3 were withdrawn at their
request or at the investigators’ initiative for lack of
compliance. Twenty-four men (10 white and 14 African
Americans) completed the study.
Subjects who qualified for the study were invited for a
second visit to do an extended fat-tolerance test. The test was
designed to evaluate beta-oxidation of fatty acids by
simultaneously measuring 3-b-hydroxybutyrate, NEFA,
and plasma TG at baseline (postabsorptive state) and during
intake of an oral fat challenge (postprandially). Briefly, this
test involved an oral administration of heavy cream (dairy
heavy cream, 40% [w/v] fat emulsion, with a ratio of
polyunsaturated to saturated fat [P/S ratio] of 0.06 and
containing 0.001% [w/v] cholesterol and 2.8% [w/v] carbo-
hydrates). The drink was divided in hourly doses according
to body weight estimating a rate of fat administration of
200 mg/kg of body weight per hour given over a 10-hour
period. Arterialized blood samples were collected from a
hand vein that had been pre-warmed in an isothermal box as
detailed previously.3 The blood samples were drawn at230,
215, 0, 30, 60 minutes and hourly for 9 additional hours.
Levels of fasting and postprandial insulin and glucagon
weremeasured by radioimmunoassay (Millipore Co, Boston,
MA). Chylomicron TGwas defined as the TG increment over
baseline TG during dietary fat loading.
The key parameters measured in the study included
baseline and postprandial levels of plasma TG, NEFA, 3-b-
hydroxybutyrate, insulin, and glucagon. Previous studies
have shown that during continuous feeding of dietary fat a
steady state in plasma TG is achieved from 5 to 10 hours,
and this observation was reproduced in this study (Fig. 1);
for this reason, hourly values during this period were aver-
aged and represented postprandial values. Data for indepen-
dent variables (anthropometric and metabolic) are
summarized as means 6 SD. Comparisons of means for
fasting baseline to postprandial levels of 3-b-hydroxybuty-
rate, nonesterified fatty acids and TGs were done by 2-
sample t test. Data not normally distributed were compared
Table 1 Subject demography and baseline metabolic parameters
Parameters
Europids African American
Mean 6 standard deviation
Number of subjects 10 14
Age (y) 30 6 11 40 6 14x
BMI (kg/m2) 23.6 6 3.4 24.2 6 2.1
Waist circumference (cm) 81.3 6 6.9 80.2 6 6.8
Hip circumference (cm) 96.9 6 8.6 92.8 6 6.2
Waist/height ratio 0.45 6 0.03 0.46 6 0.04
Glucose (mg/dL) 86 6 7 87 6 9
Triglycerides (mg/dL) 76 6 23 65 6 23
HDL cholesterol (mg/dL) 49 6 9 56 6 16
Total cholesterol (mg/dL) 167 6 32 167 6 39
LDL (mg/dL) 102 6 26 98 6 37
Postabsorptive*
3-b-hydroxybutyrate (mmoles/L)‡ 82 (58–244) 119 (50–203)
NEFA (mmoles/L) 487 6 202 492 6 193
Triglycerides (mg/dL) 64 6 32 58 6 24
Postprandial†
3-b-hydroxybutyrate (mmoles/L)‡ 729 (393–823) 801 (426–1015)
NEFA (mmoles/L) 891 6 153 917 6 184
Triglycerides (mg/dL) 132 6 69 138 6 94
*Postabsorptive: measurements done after a 12-hour fast.
†Postprandial: measurements done during a fat tolerance test of 10-hour duration using a dose of 200-mg fat drink/h/kg of body weight.
‡Median levels with respective 25th and 75th percentile levels. There are no significant differences in anthropometric and metabolic parameters
between the two groups.
xSignificantly higher; P , .05.
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was estimated by the method of Grundy and Mok.6
Results
African American and Europid volunteers had similar
anthropometric characteristics and metabolic profiles
(Table 1). For this reason, they were combined into one
data set for analysis. For the group as a whole, levels of
fasting 3-b-hydroxybutyrate correlated positively with fast-
ing levels of plasma NEFA (Fig. 2A) and inversely withFigure 2 Baseline (postabsorptive) levels of 3-b-hydroxybutyrate as a
triglycerides (B). Log of 3-b-hydroxybutyrate correlated positively with
with the metabolic relation of precursor product. In contrast, levels of 3-b
(B). Normal levels of plasma triglyceride are likely influenced by the efasting levels of plasma TG (Fig. 2B). There was a nonsig-
nificant trend for an inverse relation between fasting insulin
concentrations and 3-b-hydroxybutyrate; likewise, no cor-
relation was noted for glucagon against 3-b-hydroxybuty-
rate (data not shown).
During the fat-tolerance test, levels of plasma postpran-
dial TG, nonesterified fatty acid, and 3-b-hydroxybutyrate
increased by 55%, 85%, and 359%, respectively (Table 2). A
positive correlation was observed between postprandial
levels of 3-b-hydroxybutyrate and levels of NEFA
(Fig. 3A) and with the half-life of chylomicron TG (Fig. 3B).function of plasma levels of nonesterified fatty acids (A) or plasma
levels of nonesterified fatty acids (A). This association is consistent
-hydroxybutyrate are inversely correlated with plasma triglyceride
xtent of hepatic fatty acid oxidation.
Table 2 Levels of lipids and hormones during and extended




Triglycerides (mg/dL) 60 6 27 135 6 83*
Nonesterified fatty acids
(mmol/L)
490 6 192 906 6 169*
3-b-hydroxybutyrate
(mmol/L)
172 6 244 790 6 435*
Insulin (pmol/L) 20.6 6 9.5 22.7 6 8.8
Glucagon (pmol/L) 22.3 6 6.3 27.3 6 10.3
Insulin/glucagon ratio 0.91 6 0.23 0.88 6 0.34
*P , .001; Postprandial levels are significantly higher than the
baseline levels.
286 Journal of Clinical Lipidology, Vol 10, No 2, April 2016Finally, there were no significant changes in the plasma
levels of insulin or glucagon (or the ratio of insulin/glucagon)
between fasting and the postprandial state (Table 2).Discussion
In this study of nonobese, normotriglyceridemic men,
fasting levels of 3-b-hydroxybutyrate correlated inversely
and significantly with fasting plasma TGs. This finding is
consistent with an inverse linkage between fatty acid
oxidation and secretion of triglyceride-rich lipoproteins
and most likely, is mediated by hepatic levels of malonyl-
CoA.7–9 The latter inhibits carnitine palmitoyltransferase 1
(CPT-1), which initiates the transfer of fatty acids into
mitochondria for oxidation. Blockage of transfer of fatty
acids into mitochondria by malonyl-CoA should decrease
fatty acid oxidation (as reflected by lower 3-b-hydroxybu-
tyrate levels) and increase fatty acid incorporation into
triglyceride-rich lipoproteins (as reflected by plasma TG
concentrations). Our current findings thus suggest inverse
linkage between fatty acid oxidation and triglyceride levels
throughout the normal range of plasma triglyceride. Previ-
ously, we reported a similar pattern in moderately obese
men with hypertriglyceridemia.3 Prior hypertriglyceridemic
patients had a lower fatty acid oxidation than matchedFigure 3 Levels of postprandial 3-b-hydroxybutyrate correlated positi
turn, postprandial levels of 3-b-hydroxybutyrate increased with a prolopersons with normotriglyceridemia. Previous findings for
correlation between triglycerides and 3-b-hydroxybutyrate
are shown for the fasting state in Figure 4.3 Similar results
from the current and previous study3 also were observed in
the postprandial studies although meal challenges were
somewhat different. Our present results suggest a consistent
pattern that has a strong biologic rationale.
Other factors are known to affect fatty acid oxidation.
For example, AMP-activated protein kinase is reported to
enhance fatty acid oxidation through the acetyl-CoA
carboxylase-malonyl-CoA-CPT-1 signaling axis.10 More-
over, peroxisome proliferator-activated receptor alpha,
which is expressed mainly in liver, induces genes for
beta-oxidation and ketogenesis.11 Other factors, very
possibly, could affect fatty acid oxidation and reciprocally,
plasma TG concentrations. For example, Bray and Krauss12
reported an inverse relationship between whole-body fat
oxidation and triglyceride levels.
In the postprandial state, NEFA levels essentially doubled
compared to the fasting state. This increase has been
attributed to a failure of adipose tissue to remove all newly
hydrolyzed fatty acids from chylomicrons. This effect has
been called spillover of fatty acids.13 An excess of NEFA in
plasma could contribute to direct uptake by liver and muscle.
Evidence that the liver is a major target from fatty-acid spill-
over was more than 4-fold rise in beta hydroxybutyrate in
the postprandial state. An increase in fatty acid oxidation
should help to prevent a rise in hepatic triglyceride concen-
tration. The increase in beta hydroxybutyrate was propor-
tional to the level of postprandial NEFA concentrations.
This finding likewise supports a direct effect of fatty acid
oxidation to protect against development of fatty liver.
An interesting finding was that the rise in postprandial 3-
b-hydroxybutyrate was correlated with estimated chylomi-
cron triglyceride halflife. A delay in chylomicron clearance
suggests decreased rate of triglyceride lipolysis. Our
findings are consistent with a greater hepatic uptake of
chylomicron remnants by the liver and a secondary increase
in fatty acid oxidation. For example, Donnelly et al.14 have
presented evidence that one source of hepatic triglyceride is
direct uptake of chylomicrons or their remnants by the liver.
A final observation of interest was the lack of changes in
plasma levels of insulin or glucagon (or the ratio of insulin/vely with the levels of postprandial nonesterified fatty acids (A). In
nged residence time of chylomicron triglyceride in plasma (B).
Figure 4 Plots of levels of baseline 3-b-hydroxybutyrate and
plasma triglyceride from a previously study cohort of men with
a broad spectrum of plasma triglycerides.3 The curvilinear associ-
ation of 3-b-hydroxybutyrate with plasma triglyceride is consistent
with the results reported in this study. Normotriglyceridemic sub-
jects have a higher level of 3-b-hydroxybutyrate and as the triglyc-
eride levels rise, levels of 3-b-hydroxybutyrate are not linearly
associated with the triglyceride levels. These data support the
contention that low levels of plasma triglyceride result from an
efficient oxidation of nonesterified fatty acids.
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Several studies suggest that circulating fatty acids influence
pancreatic secretion of insulin.15–17 However, in our study,
a marked increase in NEFA levels in the postprandial state
failed to acutely increase insulin concentrations. Of course,
it is possible that chronic elevations of NEFA could modify
beta-cell function. But the design of the present study al-
lowed for the testing of the effects of acute rises in
NEFA on beta-cell function.
Limited studies suggest that fatty acids stimulate the
secretion of glucagon.18,19 However, the failure of a post-
prandial NEFA to raise glucagon levels raises doubt on a
direct, acute action of NEFA on glucagon release by
beta-cells.
In summary, the present study supports the concept that
plasma TG levels are inversely related to fatty acid
oxidation by the liver. It raises the possibility that the fatty
acid oxidation pathway is a potential target of intervention
to prevent both fatty liver and hypertriglyceridemia.Acknowledgments
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